Thomas A. Fitzgerald's most recent trade in TransCode Therapeutics Inc was a trade of 650,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 14, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TransCode Therapeutics Inc | Thomas A. Fitzgerald | Director, Interim CEO, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 650,000 | 650,000 | - | - | Stock Option (right to buy) | |
| TransCode Therapeutics Inc | Thomas A. Fitzgerald | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| TransCode Therapeutics Inc | Thomas A. Fitzgerald | Director, Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.27 per share. | 16 Jun 2022 | 12,000 | 139,377 | - | 1.3 | 15,240 | Common Stock |
| TransCode Therapeutics Inc | Thomas A. Fitzgerald | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| TransCode Therapeutics Inc | Thomas A. Fitzgerald | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 33,000 | 33,000 | - | - | Stock Option (Right to Buy) |